Medications' impact on oral health

Journal of the American Dental Association

Volumn 135, Issue 10, 2004, Pages 1440-1448

  Ciancio, Sebastian G ^a,b  

^a ADA Council on Scientific Affairs   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANOREXIGENIC AGENT; ANTACID AGENT; ANTI ACNE AGENT; ANTIALLERGIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; ANTITUSSIVE AGENT; BENAZEPRIL; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; CARBAMAZEPINE; CHLORPROPAMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLINDAMYCIN; COTYLBUTAZONE; DECONGESTIVE AGENT; DIFLUNISAL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; EPROSARTAN; FLURBIPROFEN; FOSINOPRIL; FUROSEMIDE; IBUPROFEN; IRBESARTAN; LISINOPRIL; LOSARTAN POTASSIUM; METHYLDOPA; MOEXIPRIL; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOBARBITAL; PERINDOPRIL; PHENOBARBITAL; PHENYTOIN; QUINAPRIL; RAMIPRIL; SALAZOSULFAPYRIDINE; SECOBARBITAL; SEDATIVE AGENT; SULFAFURAZOLE; SULFAMETHOXAZOLE; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ANXIETY DISORDER; BLEEDING; DENTAL CARE; DENTAL HEALTH; DENTISTRY; DISEASE ASSOCIATION; ERYTHEMA MULTIFORME; HEART PALPITATION; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; LICHENOID; LIVER TOXICITY; MOUTH HYGIENE; MOUTH MUCOSA; PSYCHOSIS; REVIEW; SALIVARY GLAND; SIDE EFFECT; STROKE; WOUND HEALING; XEROSTOMIA;

EID: 7044222045     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2004.0055     Document Type: Article

References (52)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
2. Clark DB. Dental care for the patient with bipolar disorder. J Can Dent Assoc 2003;69(1):20-4.
3. McClain DL, Bader JD, Daniel SJ, Sams DH. Gingival effects of prescription medications among adult dental patients. Spec Care Dentist 1991;11(1):15-8.
4. Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev 2003;11(2):73-93.
5. Navazesh M; ADA Council on Scientific Affairs and Division of Science. How can oral health care providers determine if patients have dry mouth? JADA 2003;134:613-20.
6. Roberts IF, Roberts GJ. Relation between medicines sweetened with sucrose and dental disease. Br Med J 1979;2(6181):14-6.
7. Shaw L, Glenwright HD. The role of medications in dental caries formation: need for sugar-free medication for children. Pediatrician 1989;16(3-4):153-5.
8. Durward C, Thou T. Dental caries and sugar-containing liquid medicines for children in New Zealand. N Z Dent J 1997;93(414):124-9.
9. Steele JG, Sheiham A, Marcenes W, Fay N, Walls AW. Clinical and behavioural risk indicators for root caries in older people. Gerodontology 2001;18(2):95-101.
10. Touger-Decker R, van Loveren C. Sugars and dental caries. Am J Clin Nutr 2003;78:881S-92S.
11. Anusavice KJ. Dental caries: risk assessment and treatment solutions for an elderly population. Compend Contin Educ Dent 2002;23(10 supplement):12-20.
12. Butt GM. Drug-induced xerostomia. J Can Den Assoc 1991;57:391-3.
13. Guggenheimer J, Moore PA. Xerostomia. JADA 2003;134:61-9.
14. Cohen G, Mandel L, Kaynar A. Salivary complaints: a manifestation of depressive mental illness. N Y State Dent J 1990;56(10):31-3.
15. Amerongen AV, Veerman EC. Saliva: the defender of the oral cavity. Oral Dis 2002;8(1):12-22.
16. Torres SR, Peixoto CB, Caldas DM, et al. Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:149-54.
17. Papas AS, Joshi A, MacDonald SL, Maravelis-Splagounias L, Pretara-Spanedda P, Curro FA. Caries prevalence in xerostomic individuals. J Can Dent Assoc 1993;59:171-4, 177-9.
18. Beck JD, Kohout FJ, Hunt RJ, Heckert DA. Root caries: physical, medical and psychosocial correlates in an elderly population. Gerodontics 1987;3:242-7.
19. Streckfus CF, Strahl RC, Welsh S. Anti-hypertension medications: an epidemiological factor in the prevalence of root decay among geriatric patients suffering from hypertension. Clin Prev Dent 1990;12(3):26-9.
20. Byrne BE. Oral manifestations of systemic agents. In: Ciancio SG, ed. ADA guide to dental therapeutics. 3rd ed. Chicago: American Dental Association; 2003:504-50.
21. Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med 2004;15(1):28-46.
22. Ackerman BH, Kasbekar N. Disturbances of taste and smell induced by drugs. Pharmacotherapy 1997;17:482-96.
23. Hall R. Angioedema and ACE inhibitors. Periodont Insights 1998;1:5-6.
24. Israeli ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
25. Chin HL, Buchan DA. Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor. Ann Intern Med 1990;112:312-3.
26. Rees SR, Gibson J. Angioedema and swellings of the orofacial region. Oral Dis 1997;3(1):39-42.
27. Poliak SG, DiGiovanna JJ, Gross EG, Gantt G, Peck GL. Minocycline-associated tooth discoloration in young adults. JAMA 1985;20:2930-2.
28. Ziskin DE, Stowe LR, Zegarelli EV. Dilantin hyperplastic gingivitis. Am J Orthod 1941;27:350-4.
29. Baden E. Sodium dilantin gingival hyperplasia and conservative treatment: a case report. J Dent Med 1950;5:46-9.
30. Ciancio SG, Yaffe SJ, Catz CC. Gingival hyperplasia and diphenylhydantoin. J Periodontol 1972;43:411-4.
31. Hall WB. Dilantin hyperplasia: a preventable lesion. J Periodontal Res 1969;4:36-7.
32. Nakade O, Baylink DJ, Lau KH. Phenytoin at micromolar concentrations is an osteogenic agent for human-mandibule-derived bone cells in vitro. J Dent Res 1995;74:331-7.
33. Cunat JJ, Ciancio SG. Diphenylhydantoin sodium: gingival hyperplasia and orthodontic treatment. Angle Orthod 1969;3:182-5.
34. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol 1999;70(1):63-7.
35. Nishikawa S, Tada H, Hamasaki A, et al. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. J Periodontol 1991;62(1):30-5.
36. Nuki K, Cooper SH. The role of inflammation in the pathogenesis of gingival enlargement during the administration of diphenylhydantoin sodium in cats. J Periodontal Res 1972;7(2):102-10.
37. Stone C, Eshenaur A, Hassell T. Gingival enlargement in cyclosporine treated multiple sclerosis patients. J Dent Res 1989;68:285-9.
38. Iacopino AM, Doxey D, Cutler CW, et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol 1997;68(1):73-83.
39. Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol 1991;18(2):107-10.
40. Ciancio SG, Bartz NW Jr, Lauciello FR. Cyclosporine-induced gingival hyperplasia and chlorhexidine: a case report. Int J Periodontics Restorative Dent 1991;3:241-5.
41. Sindet-Pedersen S, Ramstrom G, Bernvil S, Blomback M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989;320:840-3.
42. Ciancio SG. Herbal agents and oral health. Biol Ther Dent 2002;18:1-2.
43. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004;116:478-85.
44. Kribbs PJ, Chesnut CH 3rd, Ott SM, Kilcoyne RF. Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent 1989;62:703-7.
45. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-53.
46. Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-26.
47. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antimicrobial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987;66:1310-4.
48. Golub LM, Evans RT, McNamara TF, Lee HM, Ramamurthy NS. A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann N Y Acad Sci 1994;732:96-111.
49. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000;71: 521-32.
50. Ciancio SG, Genco JR. The use of antibiotics in periodontal disease. Int J Periodont Restor Dent 1983;3(6):54-71.
51. Williams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J Periodontol 1989;60:485-90.
52. Feldman RS, Szeto B, Chauncey HH, Goldhaber P. Non-steroidal anti-inflammatory drugs in the reduction of human alveolar bone loss. J Clin Periodontol 1983;10(2):131-6.